Literature DB >> 8681941

The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.

G H Gudmundsson1, B Agerberth, J Odeberg, T Bergman, B Olsson, R Salcedo.   

Abstract

The peptide FA-LL-37, previously termed FALL-39, was originally predicted from on ORF of a cDNA clone isolated from a human bone marrow library. This peptide was synthesized and found to have antibacterial activity. We have now characterized and sequenced the complete gene for FA-LL-37, termed FALL39. It is a compact gene of 1963 bp with four exons. Exons 1-3 code for a signal sequence and the cathelin region. Exon 4 contains the information for the mature antibacterial peptide. Our results indicate that FALL39 is the only member of the cathelin gene family present in the human genome. Potential binding sites for acute-phase-response factors are identified in the promoter and in intron 2. A possible role for the cytokine interleukin-6 in the regulation of FALL 39 is discussed. Anti-(FA-LL-37) IgG located the peptide in granulocytes and we isolated the mature peptide from these cells after degranulation. Structural analysis determined the mature peptide to be LL-37. To obtain LL-37 for antibacterial assays, synthetic FA-LL-37 was degraded with dipeptidyl-peptidase I. This analysis showed that mature LL-37 is a potent antibacterial peptide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8681941     DOI: 10.1111/j.1432-1033.1996.0325z.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  151 in total

1.  The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa.

Authors:  J Malm; O Sørensen; T Persson; M Frohm-Nilsson; B Johansson; A Bjartell; H Lilja; M Ståhle-Bäckdahl; N Borregaard; A Egesten
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 2.  Antimicrobial polypeptides in host defense of the respiratory tract.

Authors:  Tomas Ganz
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6.

Authors:  M Frohm Nilsson; B Sandstedt; O Sørensen; G Weber; N Borregaard; M Ståhle-Bäckdahl
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 4.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

Review 5.  Antimicrobial peptides: current status and therapeutic potential.

Authors:  Andreas R Koczulla; Robert Bals
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  High-yield expression of isotopically labeled peptides for use in NMR studies.

Authors:  Darrin A Lindhout; Angela Thiessen; Dean Schieve; Brian D Sykes
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

Review 7.  Mammalian antibiotic peptides.

Authors:  P Síma; I Trebichavský; K Sigler
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 8.  Endogenous production of antimicrobial peptides in innate immunity and human disease.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

Review 9.  Epithelial antimicrobial defence of the skin and intestine.

Authors:  Richard L Gallo; Lora V Hooper
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

10.  The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation.

Authors:  Danielle Minns; Katie J Smith; Virginia Alessandrini; Gareth Hardisty; Lauren Melrose; Lucy Jackson-Jones; Andrew S MacDonald; Donald J Davidson; Emily Gwyer Findlay
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.